Actual ambulatory care in patients with type 2 diabetes mellitus in Russian Federation according to open label prospectiveobservational study DIA-CONTROL

Código QR

Actual ambulatory care in patients with type 2 diabetes mellitus in Russian Federation according to open label prospectiveobservational study DIA-CONTROL

This review presents a comprehensive analysis of actual ambulatory care in patients with type 2 diabetes mellitus provided in 10 federal subjects withinthe period of 1 year. The analysis is based on results from non-interventional open label prospective observational study DIA-CONTROL, whichincluded...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Marina Vladimirovna Shestakova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2011
Materias:	prospective observational study treatment type 2 diabetes mellitus dpp-4 inhibitors Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/941e982124314484bf8b1da8b08d4a97
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
por: Marina Vladimirovna Shestakova
Publicado: (2010)

Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
por: Alexander Sergeevich Ametov, et al.
Publicado: (2010)

Control of type 2 diabetes mellitus: problems and prospects for their solution
por: Tatiana Ivanovna Romantsova, et al.
Publicado: (2009)

Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population
por: Anna A. Mosikian, et al.
Publicado: (2018)

Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
por: Editorial team Diabetes Mellitus
Publicado: (2012)

New prospects in the treatment of diabetes mellitus
por: Minara Shamkhalovna Shamkhalova, et al.
Publicado: (2012)

Rannyaya kombinirovannaya terapiya pri sakharnom diabete 2 tipa
por: Alexander Sergeevich Ametov, et al.
Publicado: (2011)

First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients
por: Karina Oganesovna Galstyan, et al.
Publicado: (2016)

Russian Association of Endocrinologists reports commencement of Trajenta clinical use
por: Editorial team Diabetes Mellitus
Publicado: (2012)

Epidemiology of diabetes mellitus in Russian Federation: clinical and statistical report according to the federal diabetes registry
por: Ivan Ivanovich Dedov, et al.
Publicado: (2017)

Vildagliptin and its role in the treatment of diabetes mellitus
por: Yury Shavkatovich Khalimov
Publicado: (2010)

A1chieve Program in Russian Federation: a multicenter prospective observational study of insulin analogue treatment efficiency and safety in daily management of patients with type 2 diabetes mellitus, who startand intensify insulin treatment having never received it before
por: Marina Vladimirovna Shestakova
Publicado: (2012)

Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
por: Elena Valer'evna Biryukova
Publicado: (2014)

Modern antihyperglycemic agents prescribed in Russia for type 2 diabetes mellitus
por: Yury Ivanovich Suntsov
Publicado: (2012)

Diabetes mellitus as an economic problem in Russian Federation
por: Ivan Ivanovich Dedov, et al.
Publicado: (2016)

Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
por: Lyudmila Viktorovna Nedosugova, et al.
Publicado: (2014)

Vildagliptin: the first innovative DDP-4 inhibitor
por: Edvin Villkhauer
Publicado: (2010)

Second line therapy in type 2 diabetes: legacy effect activation
por: Ekaterina A. Shestakova
Publicado: (2017)

National register of diabetes mellitus in Russian Federation.
por: Ivan Ivanovich Dedov, et al.
Publicado: (2015)

Heart failure in diabetes: effects of anti-hyperglycemic drug therapy
por: Gagik R. Galstyan, et al.
Publicado: (2016)

The new drug saxagliptin is now registrated in Russia
por: Editorial team Diabetes Mellitus
Publicado: (2010)

Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
por: Taras S. Panevin, et al.
Publicado: (2020)

Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
por: Stefan D. Anker
Publicado: (2019)

Type 2 diabetes mellitus in elderly patients treated with endocrinologists in clinical practice
por: Elena V. Biryukova
Publicado: (2019)

Epidemiology of cardiovascular diseases among patients with diabetes mellitus according to the federal diabetes register of the Russian Federation (2013–2016)
por: Viktor Y. Kalashnikov, et al.
Publicado: (2019)

Expert committee on introduction of incretin-based therapy in Russia: advance and failure
por: Editorial team Diabetes Mellitus
Publicado: (2012)

Diabetes mellitus in children and adolescents according to the Federal diabetes registry in the Russian Federation: dynamics of major epidemiological characteristics for 2013–2016
por: Ivan I. Dedov, et al.
Publicado: (2017)

Trends in the epidemiology of chronic kidney disease in Russian Federation according to the Federal Diabetes Register (2013–2016)
por: Minara S. Shamkhalova, et al.
Publicado: (2018)

Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021
por: I. I. Dedov, et al.
Publicado: (2021)

Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients
por: Alina Babenko, et al.
Publicado: (2014)

Trends in the epidemiology of diabetic retinopathy in Russian Federation according to the Federal Diabetes Register (2013–2016)
por: Dmitry V. Lipatov, et al.
Publicado: (2018)

Diabetes mellitus in Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of glucose lowering therapy according to the Federal Diabetes Register, status 2017
por: Ivan I. Dedov, et al.
Publicado: (2018)

IMPROVE observational program: safety and effectiveness of biphasic insulin aspart 30 in routine clinical practice. Overview of starting characteristics of the Russian patient cohort
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2009)

Efficacy and safety of treatment with human insulin analogues in daily management of insulin naive patients with type 2 diabetes mellitus: results of multicenter 52-week observational study A1chive
por: Marina Vladimirovna Shestakova
Publicado: (2012)

Epidemiology of acute diabetes complications (coma) according to the Federal Diabetes register of the Russian Federation (2013–2016)
por: Alexander Y. Mayorov, et al.
Publicado: (2018)

Teneligliptin in management of type 2 diabetes mellitus
por: Sharma SK, et al.
Publicado: (2016)

Prevalence of renal lesions in patients with type 1 and 2 diabetes mellitus in the Russian Federation
por: Oksana Vladimirovna Maslova, et al.
Publicado: (2009)

Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin
por: Olga Yuryevna Sukhareva, et al.
Publicado: (2016)

Heart failure in diabetes: From an increased risk to a treatment target
por: Eberhard Standl
Publicado: (2018)

Glycemia control and glucose-lowering therapy in patients with type 2 diabetes mellitus and cardiovascular disease (review of multicenter randomized trials)
por: Sergey V. Kakorin, et al.
Publicado: (2016)